Safety, Efficacy and Clinical Utility of the 5.1mm EndoRotor Powered Debridement Catheter for Treatment of Walled-Off Pancreatic Necrosis.


Journal

Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 18 07 2023
revised: 28 12 2023
accepted: 18 02 2024
medline: 3 3 2024
pubmed: 3 3 2024
entrez: 2 3 2024
Statut: aheadofprint

Résumé

Direct endoscopic necrosectomy (DEN) is a recommended strategy for treatment of walled-off-necrosis (WON). DEN uses a variety of devices including the EndoRotor (Interscope, Inc.) debridement catheter. Recently, a 5.1 mm EndoRotor with increased chamber size and rate of tissue removal was introduced. The aim of this study was to assess the efficacy and safety of this device. A multi-center cohort study was conducted at eight institutions including patients who underwent DEN with the 5.1 mm EndoRotor. The primary outcome was the number of DEN sessions needed for WON resolution. Secondary outcomes included the average percent reduction in solid WON debris and decrease in WON area per session, total time spent performing EndoRotor therapy for WON resolution, and adverse events. 64 procedures in 41 patients were included. For patients in which the 5.1 mm EndoRotor catheter was the sole therapeutic modality, an average of 1.6 DEN sessions resulted in WON resolution with an average cumulative time of 85.5 minutes. Of the 21 procedures with data regarding percent of solid debris, the average reduction was 85% +/- 23% per session. Of the 19 procedures with data regarding WON area, the mean area significantly decreased from 97.6 +/- 72.0 cm This is the first multi-center retrospective study to investigate the efficacy and safety of the 5.1 mm EndoRotor catheter for WON. Results from this study showed an average of 1.6 DEN sessions were needed to achieve WON resolution with an 85% single session reduction in solid debris and a 70% single session decrease in WON area with minimal adverse events.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Direct endoscopic necrosectomy (DEN) is a recommended strategy for treatment of walled-off-necrosis (WON). DEN uses a variety of devices including the EndoRotor (Interscope, Inc.) debridement catheter. Recently, a 5.1 mm EndoRotor with increased chamber size and rate of tissue removal was introduced. The aim of this study was to assess the efficacy and safety of this device.
METHODS METHODS
A multi-center cohort study was conducted at eight institutions including patients who underwent DEN with the 5.1 mm EndoRotor. The primary outcome was the number of DEN sessions needed for WON resolution. Secondary outcomes included the average percent reduction in solid WON debris and decrease in WON area per session, total time spent performing EndoRotor therapy for WON resolution, and adverse events.
RESULTS RESULTS
64 procedures in 41 patients were included. For patients in which the 5.1 mm EndoRotor catheter was the sole therapeutic modality, an average of 1.6 DEN sessions resulted in WON resolution with an average cumulative time of 85.5 minutes. Of the 21 procedures with data regarding percent of solid debris, the average reduction was 85% +/- 23% per session. Of the 19 procedures with data regarding WON area, the mean area significantly decreased from 97.6 +/- 72.0 cm
CONCLUSIONS CONCLUSIONS
This is the first multi-center retrospective study to investigate the efficacy and safety of the 5.1 mm EndoRotor catheter for WON. Results from this study showed an average of 1.6 DEN sessions were needed to achieve WON resolution with an 85% single session reduction in solid debris and a 70% single session decrease in WON area with minimal adverse events.

Identifiants

pubmed: 38431104
pii: S0016-5107(24)00131-7
doi: 10.1016/j.gie.2024.02.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Auteurs

Brianna Shinn (B)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Electronic address: bshinn127@gmail.com.

James Burdick (J)

Advanced Endoscopy, Dallas, Texas.

Kevin Berk (K)

Advanced Endoscopy, Dallas, Texas.

Joo Ha Hwang (JH)

Stanford University Medical Center, Palo Alto, California.

Samer El-Dika (S)

Stanford University Medical Center, Palo Alto, California.

Wassem Juakiem (W)

Stanford University Medical Center, Palo Alto, California.

Samuel Han (S)

The Ohio State University Wexner Medical Center, Columbus, Ohio.

Somashekar Krishna (S)

The Ohio State University Wexner Medical Center, Columbus, Ohio.

Mouen A Khashab (MA)

Johns Hopkins University Hospital, Baltimore, Maryland.

Shruti Mony (S)

Johns Hopkins University Hospital, Baltimore, Maryland.

Kambiz Kadkhodayan (K)

Advent Health, Orlando, Florida.

Harshit S Khara (HS)

Geisinger Medical Center, Danville, Pennsylvania.

Ali M Ahmed (AM)

University of Alabama Medical Center, Birmingham, Alabama.

Tina Boortalary (T)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Abhishek Agnohortri (A)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Anand Kumar (A)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Austin Chiang (A)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Faisal Kamal (F)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Alexander Schlachterman (A)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

David Loren (D)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Thomas Kowalski (T)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Classifications MeSH